Vonafexor (EYP001)
Alport Syndrome
Key Facts
About ENYO Pharma
ENYO Pharma is a French biotech advancing its lead compound, Vonafexor, a novel FXR agonist, through Phase 2 trials for chronic kidney diseases (CKD) and the rare genetic disorder Alport syndrome. The company leverages a unique drug discovery platform inspired by virus-host protein interactions (virus biomimetism) to develop therapeutics. With a seasoned leadership team and a focused pipeline on significant unmet needs in nephrology and metabolic diseases, ENYO aims to establish Vonafexor as a first-in-class treatment for fibrotic kidney diseases.
View full company profileAbout ENYO Pharma
ENYO Pharma is a French biotech advancing its lead compound, Vonafexor, a novel FXR agonist, through Phase 2 trials for chronic kidney diseases (CKD) and the rare genetic disorder Alport syndrome. The company leverages a unique drug discovery platform inspired by virus-host protein interactions (virus biomimetism) to develop therapeutics. With a seasoned leadership team and a focused pipeline on significant unmet needs in nephrology and metabolic diseases, ENYO aims to establish Vonafexor as a first-in-class treatment for fibrotic kidney diseases.
View full company profileAbout ENYO Pharma
ENYO Pharma is a French biotech advancing its lead compound, Vonafexor, a novel FXR agonist, through Phase 2 trials for chronic kidney diseases (CKD) and the rare genetic disorder Alport syndrome. The company leverages a unique drug discovery platform inspired by virus-host protein interactions (virus biomimetism) to develop therapeutics. With a seasoned leadership team and a focused pipeline on significant unmet needs in nephrology and metabolic diseases, ENYO aims to establish Vonafexor as a first-in-class treatment for fibrotic kidney diseases.
View full company profileAbout ENYO Pharma
ENYO Pharma is a French biotech advancing its lead compound, Vonafexor, a novel FXR agonist, through Phase 2 trials for chronic kidney diseases (CKD) and the rare genetic disorder Alport syndrome. The company leverages a unique drug discovery platform inspired by virus-host protein interactions (virus biomimetism) to develop therapeutics. With a seasoned leadership team and a focused pipeline on significant unmet needs in nephrology and metabolic diseases, ENYO aims to establish Vonafexor as a first-in-class treatment for fibrotic kidney diseases.
View full company profile